Suturable DuraGen™ PMCF Study
A Multicenter, Retrospective, Post-Market Clinical Follow-Up Study to Evaluate the Performance and Safety of Suturable DuraGen™
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Samira Lavingia
- Phone Number: 732-647-5017
- Email: samira.lavingia@integralife.com
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is between 18 and 80 years of age
- Subject has undergone either a supratentorial, an infratentorial, or a spinal procedure with the use of Suturable DuraGen™ prior to trial initiation
- Availability of post-operative assessment results.
Exclusion Criteria:
1. There are no exclusionary criteria for this study population
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Supratentorial Procedure Group
Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.
|
Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
|
|
Infratentorial Procedure Group
Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.
|
Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
|
|
Spinal Procedure Group
Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.
|
Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Outcome
Time Frame: post-up to 90 days
|
Occurrence of post-operative cerebrospinal fluid (CSF) leaks post-procedure
|
post-up to 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Adverse Event
Time Frame: Between days 30-90
|
Adverse event that occurred between days 30-90 post-operatively
|
Between days 30-90
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Andrew Tummon, Integra LifeSciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Cerebrospinal Fluid Leak
- Contraceptive Agents, Hormonal
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Reproductive Control Agents
- Contraceptive Agents, Female
- Contraceptive Agents
- Estrogens
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Estradiol
- Polyestradiol phosphate
Other Study ID Numbers
Other Study ID Numbers
- C-DGSUT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.